Skip to main content
Dryad

Vasohibin1, a new mouse cardiomyocyte IRES trans-acting factor that regulates translation in early hypoxia

Prats, Anne-Catherine1; Hantelys, Fransky2; Godet, Anne-Claire2; David, Florian2; Tatin, Florence2; Renaud-Gabardos, Edith2; Pujol, Françoise2; Diallo, Leila H.2; Ader, Isabelle3; Ligat, Laetitia2; Henras, Anthony K.2; Sato, Yasufumi4; Parini, Angelo2; Lacazette, Eric2; Garmy-Susini, Barbara2

Published Aug 24, 2020 on Dryad. https://doi.org/10.5061/dryad.nvx0k6dq7

Data files

Aug 24, 2020 version files 155.93 KB

Click names to download individual files

Abstract

Hypoxia, a major inducer of angiogenesis, triggers major changes in gene expression at the transcriptional level. Furthermore, under hypoxia, global protein synthesis is blocked while internal ribosome entry sites (IRES) allow specific mRNAs to be translated. Here, we report the transcriptome and translatome signatures of (lymph)angiogenic genes in hypoxic HL-1 mouse cardiomyocytes: most genes are induced at the translatome level, including all IRES-containing mRNAs. Our data reveal activation of (lymph)angiogenic factor mRNA IRESs in early hypoxia. We identify vasohibin1 (VASH1) as an IRES trans-acting factor (ITAF) that is able to bind RNA and to activate the FGF1 IRES in hypoxia, but which tends to inhibit several IRESs in normoxia. VASH1 depletion has a wide impact on the translatome of (lymph)angiogenesis genes, suggesting that this protein can regulate translation positively or negatively in early hypoxia. Translational control thus appears as a pivotal process triggering new vessel formation in ischemic heart.